PLA2G7 Antibody

中文名稱：

PLA2G7兔多克隆抗體
貨號：

CSB-PA08917A0Rb
規(guī)格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human colon cancer using CSB-PA08917A0Rb at dilution of 1:100

Immunohistochemistry of paraffin-embedded human pancreatic cancer using CSB-PA08917A0Rb at dilution of 1:100

Western Blot
Positive WB detected in: HepG2 whole cell lysate
All lanes: PLA2G7 antibody at 4µg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 51 kDa
Observed band size: 51 kDa
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) PLA2G7 Polyclonal antibody
Uniprot No.：

Q13093
基因名：

PLA2G7
別名：

Platelet-activating factor acetylhydrolase precursor antibody; 1 alkyl 2 acetylglycerophosphocholine esterase antibody; 1-alkyl-2-acetylglycerophosphocholine esterase antibody; 2 acetyl 1 alkylglycerophosphocholine esterase antibody; 2-acetyl-1-alkylglycerophosphocholine esterase antibody; EC 3.1.1.47 PAF acetylhydrolase PAF 2-acylhydrolase LDL associated phospholipase A2 antibody; Group VIIA phospholipase A2 antibody; Group-VIIA phospholipase A2 antibody; gVIIA PLA2 antibody; gVIIA-PLA2 antibody; LDL associated phospholipase A2 antibody; LDL PLA(2) antibody; LDL PLA2 antibody; LDL-associated phospholipase A2 antibody; LDL-PLA(2) antibody; Lipoprotein associated phospholipase A2 antibody; LP PLA2 antibody; PAF 2 acylhydrolase antibody; PAF 2 acylhydrolase LDL associated phospholipase A2 antibody; PAF 2-acylhydrolase antibody; PAF acetylhydrolase antibody; PAFA_HUMAN antibody; PAFAD antibody; PAFAH antibody; Phospholipase A2, group VII (platelet activating factor acetylhydrolase, plasma) antibody; PLA2G7 antibody; Platelet activating factor acetylhydrolase 2 antibody; Platelet activating factor acetylhydrolase antibody; Platelet-activating factor acetylhydrolase antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Platelet-activating factor acetylhydrolase protein (49-441AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，PLA2G7 Antibody (CSB-PA08917A0Rb)，的標(biāo)記方式是Non-conjugated。對于PLA2G7 Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA08917B0Rb	PLA2G7 Antibody, HRP conjugated	ELISA
FITC	CSB-PA08917C0Rb	PLA2G7 Antibody, FITC conjugated
Biotin	CSB-PA08917D0Rb	PLA2G7 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:1000-1:5000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Lipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress response. At the lipid-aqueous interface, hydrolyzes the ester bond of fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity). Specifically targets phospholipids with a short-chain fatty acyl group at sn-2 position. Can hydrolyze phospholipids with long fatty acyl chains, only if they carry oxidized functional groups. Hydrolyzes and inactivates platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), a potent proinflammatory signaling lipid that acts through PTAFR on various innate immune cells. Hydrolyzes oxidatively truncated phospholipids carrying an aldehyde group at omega position, preventing their accumulation in low-density lipoprotein (LDL) particles and uncontrolled proinflammatory effects. As part of high-density lipoprotein (HDL) particles, can hydrolyze phospholipids having long-chain fatty acyl hydroperoxides at sn-2 position and protect against potential accumulation of these oxylipins in the vascular wall. Catalyzes the release from membrane phospholipids of F2-isoprostanes, lipid biomarkers of cellular oxidative damage.
基因功能參考文獻(xiàn)：
1. The decrease of Lp-PLA2 activity in adolescents with type 2 diabetes suggests that elevated blood glucose concentrations do not have a dominant elevating effect, perhaps even a decreasing influence on Lp- PLA2 activity. PMID: 29027597
2. Polymorphisms in rs1805017 and rs1805018, additional interaction between rs1805017 and smoking, and haplotype containing the rs1805017-H and rs1805018-T alleles were associated with increased CHD risk. PMID: 29728838
3. CD163 positive macrophages have roles in lipoprotein-associated phospholipase A2 activity in atherosclerotic plaque PMID: 29101839
4. evidence that Lp-PLA2 could predict all-cause mortality and rehospitalization risk among patients with ACS undergoing PCI. PMID: 29121808
5. the relationship between two variants of apoC1 and the risk of polycystic ovary syndrome, evaluated the genotypic effects on clinical, hormonal and metabolic indexes and plasma platelet-activating factor acetylhydrolase (PAF-AH) activity, was investigated. PMID: 29636060
6. Met117 oxidation caused enhanced flexibility and decreased compactness in oxidized state. PAF binding interaction with oxidized protein was mediated only through hydrophobic interactions. PMID: 29427679
7. Persistently elevated serum concentrations of Lp-PLA2 were associated with an unfavorable outcome in patients with sepsis. PMID: 29138849
8. Resveratrol downregulates Lp-PLA2 expression by inhibiting oxidative stress via SIRT1 pathway in the THP-1-derived macrophages. PMID: 28608449
9. Elevated Lp-PLA2 mass was associated with all cause-death independently of other risk factors within one year after acute ischemic stroke. PMID: 28934604
10. PLA2G7 and PON1 are overexpressed in prostatic neoplasm patients and can be detected early in blood. PMID: 29050675
11. A PLA2G7 gene polymorphism determines the plasma levels of lipoprotein-associated phospholipase A2 activity and mass and manifests as a risk factor for atherosclerosis. PMID: 27905470
12. Conclusion RBP4 may be used as a predictive factor of diabetic nephropathy patients complicated with silent cerebral infarction (SCI) and is positively correlated with cognitive dysfunction. RBP4/Lp-PLA2/Netrin-1 pathway activation may be one of the occurrence mechanisms in diabetic nephropathy complicated with SCI. PMID: 28704853
13. Greater Lp-PLA2 activity or mass was associated with an increased risk of CHD and IS PMID: 28514697
14. Lp-PLA2 G994T gene polymorphism may be an independent risk factor of ischemic stroke in Chinese population. PMID: 28960681
15. Lifelong lower Lp-PLA2 activity was not associated with major risks of vascular or non-vascular diseases in Chinese adults. PMID: 27301456
16. phospholipase A2 Group 7 (PLA2G7), to be important in regulating tumor cell migration and a novel tumor-promoting factor in nasopharyngeal carcinoma. PMID: 27487154
17. Suggest that the plasma biomarkers Lp-PLA2 activity and mass are markers of abdominal aortic aneurysm risk after adjusting for relevant confounders. PMID: 28475940
18. The substitution of whole grains and legumes for refined rice resulted in a reduction in Lp-PLA2 activities in plasma and PBMCs partly through improved glycemic control, increased consumption of protein relative to carbohydrate, and reduced lipid peroxides. PMID: 24904022
19. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease PMID: 28502488
20. High levels of high-sensitive C-reactive protein and lipoprotein-associated phospholipase-A2 did not relate to endothelial dysfunction in ST-elevation myocardial infarction patients treated with percutaneous coronary intervention. PMID: 28110894
21. In persistent prehypertension, increased ox-LDL hydrolysis by Lp-PLA2 enhances arterial stiffness without an age-related increase in blood pressure. PMID: 28142077
22. LpPLA2 is found in both LDL and HDL and is distributed differently in men with T1D without any relationship to CAC score progression PMID: 27206945
23. In a multi-ethnic cohort without baseline cardiovascular disease, higher Lp-PLA2 mass and activity were not significantly associated with an increased risk for incident peripheral arterial disease. PMID: 28215109
24. Lipoprotein-associated phospholipase A2 as a new marker to determine cardiovascular risk in hypercholesterolemic dyslipidaemic children PMID: 27614353
25. The simultaneous presence of the PLA2G7 279VV genotype and persistence of overweight synergistically increases the risk for hypertension. PMID: 28334001
26. Elevated mass and activity of Lp-PLA2 related to inflammation and atherosclerosis may take part in the development of kidney injury and atherosclerosis in patients with chronic kidney disease. PMID: 27776715
27. Taken together, these results revealed that Lp-PLA2 silencing protected against ox-LDL-induced oxidative stress and cell apoptosis via Akt/mTOR signaling pathway in human THP1 macrophages. PMID: 27392709
28. Plasma Lp-PLA2 concentration was independently associated with coronary heart disease in Chinese patients. PMID: 28222638
29. The distribution of V279F-AA+AC genotype and R92H-AA+AG genotype in the AP group was higher than that in the control group, whereas the Severity of Acute Pancreatitis (SAP) group and SAP with multiple organ dysfunction syndrome group distributions were higher than those in the MAP group and SAP without MODS group.G-C-A, G-A-G, and G-C-G haploids formed by A379V, V279F, and R92H may be associated with AP susceptibility PMID: 28332853
30. results do not support added value of Lp-PLA2 for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor PMID: 27097870
31. High Lp-PLA2 expression is associated with type 1 diabetes. PMID: 27710915
32. This presentation aims at clarifying the involvement of Lp-PLA2 in the pathophysiology of atherosclerosis, and at assessing its interest both as a biomarker for the onset of CV events and as a therapeutic target--{REVIEW} PMID: 26499399
33. PLA2G7 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
34. A considerable portion of Chinese ischemic stroke patients are insensitive to aspirin treatment, which may be correlated with the MDR1 C3435T, TBXA2R (rs1131882), and PLA2G7 (rs1051931-rs7756935) polymorphisms. PMID: 27641736
35. Uremic environment but not inflammation per se increases plasma Lp-PLA2 activity and upregulates monocytic Lp-PLA2 mRNA expression. The highest Lp-PLA2 levels were found in the classical and not in the inflammatory subsets. Atherosclerosis also contributes to a subset-specific increase in Lp-PLA2 mRNA expression. PMID: 27992874
36. Lp-PLA2 levels in human plasma were positively associated with the severity of coronary heart disease. PMID: 27941334
37. Greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with coronary heart disease, particularly in patients with stable coronary heart disease who were not receiving therapies for inhibiting Lp-PLA2.[review] PMID: 27956130
38. Expression of LpPLA2 may be associated with obesity. Therefore, LpPLA2 mRNA expression levels may develop as an important risk predictor for vascular complications in Metabolic syndrome. PMID: 26460076
39. PLA2G7 gene expression was co-regulated by 17-beta-estradiol and promoter methylation. PMID: 27450918
40. no relationship with either proinflammatory cytokines or neopterin identified in Alzheimer disease PMID: 26828804
41. Lp-PLA2 activity in Japanese men aged 50-79 years was associated significantly and positively with IMT and plaque in the carotid artery but Mendelian randomization did not support that Lp-PLA2 is a causative factor for subclinical atherosclerosis. PMID: 26775119
42. 279Val-->Phe Polymorphism of Lp-PLA2 may lead to decrease the enzymatic activity via changes of folding kinetics and recognition to its substrate. PMID: 26595893
43. Increased plasma Lp-PLA2 activity portends increased risk of resistant hypertension. PMID: 26801405
44. These findings suggest that plasma PAF may be a potential biomarker for predicting poor bone health in postmenopausal women. PMID: 25501698
45. Studied whether the level of Lp-PLA2 is associated with subclinical atherosclerosis in patients with rheumatoid arthritis. PMID: 26504820
46. Higher Lp-PLA2 mass and activity were associated with development of both incident clinical peripheral arterial disease and low ankle brachial index. PMID: 26848158
47. A V279F loss-of-function variant in the PLA2G7 gene resulting in 50% lower activity for each copy of the variant, is common in East Asians and associated with risk of Vascular diseases. PMID: 26791069
48. It is assumed that Lp-PLA2 is involved in vascular calcification and that dp-ucMGP is a more appropriate biomarker of residual risk than Lp-PLA2 itself. PMID: 25458708
49. Cytosolic phospholipase A2 modulates TLR2 signaling in synoviocytes. PMID: 25893499
50. Lipoprotein associated phospholipase A2 activity and apolipoprotein C3 loss-of-function variants are involved in cardiovascular disease PMID: 26117401
顯示更多

收起更多
相關(guān)疾病：

Platelet-activating factor acetylhydrolase deficiency (PAFAD); Asthma (ASTHMA); Atopic hypersensitivity (ATOPY)
亞細(xì)胞定位：

Secreted, extracellular space.
蛋白家族：

AB hydrolase superfamily, Lipase family
組織特異性：

Plasma. Secreted by macrophages (at protein level).
數(shù)據(jù)庫鏈接：

HGNC: 9040

OMIM: 147050

KEGG: hsa:7941

STRING: 9606.ENSP00000274793

UniGene: Hs.584823

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human